ETView Medical, Ltd. announced appointment of David Amar, MD, to its scientific advisory board
(June 4, 2012, Tel Aviv, Israel) ETView Medical Ltd. (TASE: ETVW) announced today that it has appointed David Amar, MD, to its Scientific Advisory Board. Dr. Amar currently holds the position of Director, Thoracic Anesthesia at Memorial Sloan-Kettering Cancer Center and Professor of Anesthesiology, Weill Medical College of Cornell University (New York City, New York). Dr. Amar has published over 45 peer-reviewed scientific articles in the field of cardiothoracic anesthesia. Dr. Amar received his medical training at Loyola University of Chicago Stritch School of Medicine, and performed his residency at Albert Einstein College of Medicine and Columbia-Presbyterian Medical Center. Dr. Amar holds multiple professional society appointments, and is the Fellowship Director of Thoracic Anesthesia at the Memorial Sloan-Kettering Cancer Center.
William Edelman, CEO for ETView commented, "We are thrilled to have Dr. Amar join our Scientific Advisory Board. Dr. Amar is an internationally respected clinician focused in the area of surgical lung isolation. Dr. Amar will provide valuable advice to ETView as we continue the commercial expansion worldwide for our VivaSight airway management product line." Mr. Edelman continued, “We intend to recruit other clinicians of Dr. Amar’s caliber to join him in our Scientific Advisory Board over the next few months." Dr Amar commented, “I look forward to joining the Scientific Advisory Board of ETView Medical Ltd., to enhance the development of the next generation of products used in the area of surgical lung isolation.”
On May 23, 2012, ETView Announced US FDA Clearance of a 510(k) Pre-Marketing Notification Application for the VivaSight(TM)-DL line of Innovative Airway Devices
About the VivaSight™ Airway Management System
VivaSight™ 1 is a proprietary, single-use disposable medical device, consisting of either a single lumen (VivaSight™-SL) or a dual lumen (VivaSight™-DL) airway ventilation tube with an integrated continuous high resolution video airway imaging system permitting airway control and lung isolation during certain surgical procedures. Lung isolation is employed to provide one-lung ventilation in patients undergoing thoracic, cardiac, vascular, or esophageal surgeries.2 During lung isolation, temporary visualization of the patient airway is achieved with a fiberoptic bronchoscope while the patient is ventilated and the target lung isolated. Intraoperative surgical maneuvers often require repeated imaging and partial blocking of the airway to maintain lung isolation.3 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,4 accounting for over $250M in single-use medical disposables.5 ETView has pioneered development of the VivaSight™ platform, combining an airway
ventilation tube with integrated continuous high resolution airway imaging for patient airway control and lung isolation capability (eliminating the need for fiberoptic bronchoscope6 imaging during these procedures).
About ETView, Medical, Ltd.
ETView Medical Ltd. (TASE: ETVW) has successfully combined airway management with continuous direct airway visualization for medical professionals. ETView's patented VivaSight™ airway management portfolio consists of single-use disposable medical devices, representing either single or double lumen ventilation tubes with an integrated continuous high resolution airway imaging system. VivaSight™-SL and VivaSight™-DL are currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries.7
The Company estimations in this press release, including those estimations regarding the Company's predicted scope of business, constitute forward-looking statements, as such term is defined under the Israeli Securities Law (5728-1968), and there is no certainty that such estimations shall materialize. The Company's estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.
1 Patents Issued and Pending
2 Principles and Practices of Anesthesia for Thoracic Surgery. P. Singer (ed.) 2011
3 Anesthesia & Analgesia. 2009;108:1097–101
4 National Health Statistics Reports Number 29, October 26, 2010
5 Company estimates on file
6 Minerva Anestesiol. 2009;75(Suppl 1):1-4
7 Anesthesiology. 2006;105:471-477